Kingdom Capital
Kingdom Capital is a venture capital and private equity firm established in 2016, located in Chesterfield, Missouri. The firm focuses on early and growth-stage investments in mature and established companies across various sectors, including healthcare, technology, media, and real estate. It emphasizes sectors such as artificial intelligence, data science, therapeutics, medical devices, diagnostics, healthcare IT, and life science tools. Kingdom Capital aims to create a values-driven ecosystem that connects its investors with impactful investment opportunities, fostering collaboration with philanthropic partners through its Kingdom Capital Foundation. This strategic integration enhances the flow of capital into the philanthropic community, supporting both financial and social returns.
AstrumU is creating a new paradigm for the ‘Learn+Work’ Lifecycle based on outcomes. The 'AstrumU Platform' provides predictive insights by using artificial intelligence to translate data from students, schools and employers—delivering meaningful and lasting careers discovered through facts, not fortune.
IntEngine, operating under Tanjing Technology, specializes in developing software algorithms and chip hardware technology aimed at enhancing efficiency in everyday life. The company focuses on deep learning and machine learning algorithms, providing tailored solutions for various Internet of Things (IoT) terminal devices. In addition to offering advanced digitalization solutions for industrial users, IntEngine develops end-side AI chips that improve the functionality and security of terminal equipment, including upgrades to security monitoring systems. Through its innovative approach, the company supports the growing demand for intelligent and efficient technology in diverse applications.
Canopy Biosciences is a biotechnology company specializing in research tools for gene editing, molecular biology, and personalized medicine. Founded in 2016 and headquartered in St. Louis, Missouri, the company offers a range of products and services designed to enhance scientific discovery in biomedical research. Its gene editing technology, known as TUNR, facilitates targeted modifications in the genome by inserting polyA tracks into specific coding regions, which reduces mRNA levels and subsequently suppresses protein expression. This innovative approach supports researchers at universities, research institutions, and within the biotechnology and pharmaceutical sectors, advancing the fields of genetic engineering and gene expression analysis. Canopy Biosciences operates as a subsidiary of Bruker Corporation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.